A research team has successfully developed an innovative platform for diabetes treatment using bioink derived from pancreatic ...
Cell line-specific efficacy profiles: SIL204 showed robust activity across multiple pancreatic cancer ... intestine, spleen and stomach in the two models checked for the various organs, Panc ...
spleen and stomach in the two models checked for the various organs, Panc-1 and BxPC-3 models. Subcutaneous administration of SIL204 proved effective in reaching and treating pancreatic tumors and ...
(RTTNews) - Silexion Therapeutics (SLXN) announced positive data from preclinical studies of SIL204, its RNA interference (RNAi) therapy, in orthotopic pancreatic cancer models. These findings ...
In a study published in ACS Nano, experiments in lab models demonstrated ... nanoparticles to the spleen—a key immune organ that assists immune defense at the original pancreatic cancer site.
Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of ...
The American Cancer Society estimates that about 67,440 Americans (34,950 men and 32,490 women) will be diagnosed with pancreatic cancer this year. Of those, about 51,980 people (27,050 men and ...
The most common pathology affecting the pancreas is excess intra-pancreatic ... most have shown promise in preclinical animal models. But only thiazolidinediones, GLP-1 RAs, DPP-4 inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback